Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab
- PMID: 29363752
- DOI: 10.1111/bjh.15110
Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab
Keywords: infusion-related reaction; lymphoma; monoclonal antibody; ofatumumab; rituximab.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
